Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 12/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | RGS12 | O14924 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100450 | 0.85 | MEN1 (0.45) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL5103886 | 0.85 | KIF11 (0.53) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL3838937 | 0.85 | KIF11 (0.40) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL5100270 | 0.82 | KIF11 (0.51) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL4046310 | 0.80 | KIF11 (0.53) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL12454692 | 0.80 | CACNA2D1 (0.48) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL5555016 | 0.80 | PDE4A (0.41) | MEN1KMT2AKDM4EKIF11POLB | |
| SCHEMBL3838642 | 0.80 | KDM4E (0.45) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL4069383 | 0.79 | MEN1 (0.40) | MEN1KMT2AMAPTKDM4EGAA | |
| SCHEMBL5100445 | 0.78 | KIF11 (0.62) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1481077-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1481077-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050171122-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-04 | — | — | US | disclosed |
| EP-1481077-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003049679-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171122-A1 | Mitotic kinesin inhibitors | KIF5B, KIFC1, KIF2C | MEN1 2243/4885KMT2A 466/4885MAPT 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.